Researchers halt enrollment in ReoPro stroke trial

Citing safety concerns, Centocor and Eli Lilly have halted enrolling patients for a trial of ReoPro for acute strokes. Some patients in the trial experienced bleeding inside the skull. The trial, which was launched in October '03, looked at using ReoPro to dissolve blood clots. ReoPro is approved for reducing chest pain prior to procedures.

- read this AP article for more